Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
BACKGROUND
Human immunodeficiency virus (HIV)-infected patients are at higher risk of malignancies. In addition to traditional determinants, a specific deleterious effect of HIV and immunodeficiency is speculated. We aimed at studying the association between immunological and virological characteristics of HIV-infected patients in care and the risk of acquired immunodeficiency syndrome (AIDS)-defining and non-AIDS-defining malignancies.


METHODS
Patients consecutively enrolled in the hospital-based Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort were included if the duration of follow-up was >3 months during the period 1998-2006. Multivariate modeling used an extended Cox proportional hazards model for time-dependent covariates and delayed entry.


RESULTS
The 4194 patients included in the study developed 251 first malignancies during 22,389 person-years. A higher incidence of AIDS-defining malignancies (107 cases) was independently associated with (1) both longer and current exposures to a plasma HIV RNA level >500 copies/mL (hazard ratio [HR], 1.27 per year [P<.001] and 3.30 [P<.001], respectively) and (2) both longer and current exposure to a CD4(+) cell count <200 cells/mm(3) (HR, 1.36 per year [P<.001] and 6.33 [P<.001], respectively). A higher incidence of non-AIDS-defining malignancies (144 cases) was independently associated with longer and current exposure to a CD4(+) cell count <500 cells/mm(3) (HR, 1.13 per year [P=.01] and 2.07 [P<.001], respectively) and male sex (HR, 1.69; P=.02) but not with plasma HIV RNA level (P=.49 and P=.10 for cumulative and current exposures, respectively).


CONCLUSIONS
Uncontrolled plasma HIV RNA level was independently associated with a higher likelihood of developing AIDS-defining malignancies, whereas immunosuppression was associated with a higher risk of developing any type of malignancies. Antiretroviral treatment should aim at reaching and maintaining a CD4(+) count >500 cells/mm(3) to prevent the occurrence of malignancy, this should be integrated to malignancy-prevention policies.
Bruyand
Mathias
M
Institut National de la Santé et de la Recherche Médicale (INSERM) U897.
Thiébaut
Rodolphe
R
Lawson-Ayayi
Sylvie
S
Joly
Pierre
P
Sasco
Annie Jeanne
AJ
Mercié
Patrick
P
Pellegrin
Jean Luc
JL
Neau
Didier
D
Dabis
François
F
Morlat
Philippe
P
Chêne
Geneviève
G
Bonnet
Fabrice
F
D000328:Adult; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D015999:Multivariate Analysis; D009369:Neoplasms / Q000453:epidemiology*; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
D012367:RNA, Viral
Curr Opin Oncol. 2007 Sep;19(5):446-51
17762569
AIDS. 2008 Oct 18;22(16):2135-41
18832877
Cancer. 2004 Jul 15;101(2):317-24
15241829
Clin Infect Dis. 2009 Mar 1;48(5):640-1
19202628
Int J Epidemiol. 2005 Feb;34(1):121-30
15561752
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7
17621240
Am J Epidemiol. 1997 Oct 15;146(8):683-4
9345125
JAMA. 2006 Dec 20;296(23):2823-31
17179459
Int J Tuberc Lung Dis. 2006 Apr;10(4):378-83
16602400
AIDS. 2000 May 26;14(8):971-8
10853978
J Natl Cancer Inst. 1992 Oct 21;84(20):1593-5
1404453
Cancer. 2005 Oct 1;104(7):1505-11
16104038
Clin Infect Dis. 2006 Feb 1;42(3):411-7
16392091
Immunol Invest. 1997 Apr;26(3):351-70
9129988
Ann Intern Med. 2006 Sep 19;145(6):397-406
16983127
Eur J Cancer. 2007 Sep;43(14):2117-23
17764927
J Clin Oncol. 2003 Sep 15;21(18):3447-53
12972519
JAMA. 2001 Apr 4;285(13):1736-45
11277828
AIDS. 2003 May 23;17(8):1179-93
12819520
J Interferon Cytokine Res. 1995 Mar;15(3):261-8
7584673
Lancet. 2007 Jul 7;370(9581):59-67
17617273
Rev Epidemiol Sante Publique. 2003 Feb;51(1 Pt 1):3-30
12684578
AIDS. 2006 Aug 1;20(12):1645-54
16868446
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):590-8
18645512
IARC Sci Publ. 1987;(82):1-406
3329634
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
1361652
Blood. 2004 Aug 15;104(4):942-7
15117761
Clin Infect Dis. 2009 Mar 1;48(5):633-9
19202627
AIDS. 2004 Nov 19;18(17):2285-93
15577541
Science. 1997 Mar 7;275(5305):1481-5
9045614
Science. 1994 Dec 16;266(5192):1865-9
7997879
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32
15770006
HIV Med. 2007 Nov;8(8):547-54
17944688